Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Olmesartan Comparison to Losartan in Hypertensive Subjects: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan Comparison to Losartan in Hypertensive Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949884).
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OLOLIndependent statistical analysis of Our Lifestyles Our Lives: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02965729).
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction – DOSE Finding Study: Complete Statistical AnalysisIndependent statistical analysis of Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OLTERMSIndependent statistical analysis of Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OLYMPIAIndependent statistical analysis of TearCare System to Treat Dry Eye Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03857919).
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- OLYMPUSIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study: Complete Statistical AnalysisIndependent statistical analysis of Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13): Complete Statistical AnalysisIndependent statistical analysis of Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02531438).
- Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04779242).
- Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Omalizumab in the Treatment of Peanut Allergy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in the Treatment of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949078).
- Omarigliptin (MK-3102) Clinical Trial – Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): Complete Statistical AnalysisIndependent statistical analysis of Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): primary endpoint results, effect estimate with confidence interval,…
- Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00511810).
- Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01694667).
- OmegaREMODELIndependent statistical analysis of Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- OMS302-ILR-003Independent statistical analysis of Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OMWaNAIndependent statistical analysis of Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ON TRAXIndependent statistical analysis of Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- On-OffIndependent statistical analysis of On Versus Off Pump Myocardial Revascularization Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290952).
- ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management: Complete Statistical AnalysisIndependent statistical analysis of ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ONBOARDIndependent statistical analysis of Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04672655).
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03394027).
- Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00837200).
- Once Versus Twice Daily Iron Supplementation in Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Once Versus Twice Daily Iron Supplementation in Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02839096).
- Once-Daily Asenapine for Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Once-Daily Asenapine for Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01549041).
- Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures: Complete Statistical AnalysisIndependent statistical analysis of Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures: primary endpoint results, effect estimate with confidence interval,…
- Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- onceMRKIndependent statistical analysis of Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292): primary…
- One Year Study of Rifaximin Delayed Release (DR) in Crohn’s Disease: Complete Statistical AnalysisIndependent statistical analysis of One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: Complete Statistical AnalysisIndependent statistical analysis of One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Online MBCT Program for University Students: Complete Statistical AnalysisIndependent statistical analysis of Online MBCT Program for University Students: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05804877).
- Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: Complete Statistical AnalysisIndependent statistical analysis of Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ONPEDIndependent statistical analysis of Oral Naltrexone In Pediatric Eating Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073679).
- ONTAKIndependent statistical analysis of A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD): primary endpoint results, effect estimate with confidence…
- Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Study Telmisartan and Amlodipine in Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study Telmisartan and Amlodipine in Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00614380).
- Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with…
- Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…